* Immunocore Holdings PLC IMCR.OQ IMCR.O is expected
to show a
rise in quarterly revenue when it reports results on February
26 for the period ending December 31 2024
* The Abingdon Oxfordshire-based company is expected to
report a
22.4% increase in revenue to $85.909 million from $70.16 million
a year ago, according to the mean estimate from 15 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Immunocore Holdings PLC
is for
a loss of 26 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Immunocore
Holdings PLC is $67.00, above its last closing price
of $29.92.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2024 -0.35 -0.35 0.17 Beat 148.4
Jun. 30 2024 -0.55 -0.48 -0.23 Beat 51.7
Mar. 31 2024 -0.38 -0.36 -0.49 Missed -35.4
Dec. 31 2023 -0.28 -0.28 -0.40 Missed -47
Sep. -0.35 -0.35 0.05 Beat 113.8
30 2023
Jun. 30 2023 -0.40 -0.41 -0.36 Beat 9.7
Mar. 31 2023 -0.45 -0.39 -0.43 Missed -10.7
Dec. 31 2022 -0.01 0.00 -0.63 Missed -2,523
,264.5
This summary was machine generated February 24 at 14:04 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)